Grants Attract Top Researchers to Copenhagen
News Jan 28, 2013
The two professors will now move their research to University of Copenhagen. It is the first time the Foundation awards these new individual researcher grants.
The Danish research community will now be enriched by two of the world's leading names within cell regulation and bacterial persistence.
Professor Stephen M. Cohen, National University of Singapore, and Professor Kenn Gerdes, Newcastle University (UK), are the first to receive the Novo Nordisk Foundation's new Laureate Research Grants. The 7-year grants, which have been offered internationally in open competition, are of DKK 40 million (approx. € 5.36 million) each and are thus the largest individual research grants the Foundation has awarded to date. The aim of the grants is to bring international leading researchers within biomedicine and biotechnology to Denmark and thereby strengthen Danish research. The two professors will be employed at the University of Copenhagen and will be in Denmark for at least seven years.
"I am very pleased that Professor Stephen M. Cohen and Professor Kenn Gerdes choose to move their research to the University of Copenhagen. Their arrival means that the University will gain significant new research areas that may provide important contributions to the research at the Faculty of Health and Medical Sciences and the Faculty of Science," says Rector Ralf Hemmingsen, University of Copenhagen.
Genetic cooperation and bacterial life
Professor Stephen M. Cohen, 56 years of age, has amongst other scientific achievements during his career, made a major contribution to the understanding of how micro-RNA helps to control how a cell develops. Cohen's research in Denmark will focus primarily on the role that microRNA plays in relation to cancer. The research will help us to understand how different genes cooperate in the development of cancer and metastases. The ultimate goal is to identify new biomarkers for diagnostics and new targets for treatment.
Professor Kenn Gerdes, 58 years of age, has carried out pioneering research in persistence of bacterial infections. His research group has recently shown that the genetic elements known as toxin-antitoxin genes makes it possible for bacteria to stay alive in their host organism, even though they are sensitive to antibiotics. This can cause recurring or chronic infections. Gerdes' research in Denmark will focus on increasing our understanding of how bacteria survive and will promote the development of new methods for the control of relapsing and chronic infections.
Stephen M. Cohen and Kenn Gerdes will now start building their research groups at the University and will over the next few years gradually move all their operations to Copenhagen, so that in 2015 they will be fully employed at the University of Copenhagen.
"With the new, substantial Laureate Research Grants, the Novo Nordisk Foundation aims to bring some of the world's best researchers to Denmark. This will strengthen Danish research in both the short and long view, while also contributing to the Foundation’s vision of making Denmark an international beacon for research within biomedicine and biotechnology. This will be achieved by developing and strengthening the country's scientific skills, training researchers and achieving world class scientific results," says chairman of the Board of the Novo Nordisk Foundation, Ulf. J. Johansson.
Blood Sample Detection Method for Multiple Sclerosis DiscoveredNews
A method for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research team. The process will avoid the invasive, painful process of collecting fluid from the brain and spineREAD MORE
Single-Dose Vaccine Could Provide Faster Protection in Cholera EpidemicsNews
Each year there are more than three million cases of cholera worldwide, a disease transmitted through contaminated food and water that hits developing countries particularly hard. While the standard regimen for protecting against cholera with existing non-living oral cholera vaccines includes administering two doses over a two-week period, research now shows that giving a stronger single-dose of a live oral vaccine could be an effective tool in controlling outbreaks more quickly.READ MORE